News | November 17, 2025
Briefs: Zydus, Divi's Laboratories and Relonchem
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
The company expects meaningful revenue contribution from this long-term agreement
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The proposed facility is expected to be operational around January, 2027
The delegation's visit covered a wide range of topics
Forex gains stood at Rs 20 crore for the quarter
Divi's Laboratories has reported total income of Rs. 2,529 crores during the period ended June 30, 2025
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
